Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACAD |
---|---|---|
09:32 ET | 16783 | 16.22 |
09:34 ET | 3600 | 16.33 |
09:36 ET | 300 | 16.34 |
09:38 ET | 7000 | 16.35 |
09:39 ET | 846 | 16.3499 |
09:41 ET | 2342 | 16.33 |
09:43 ET | 1200 | 16.33 |
09:45 ET | 1600 | 16.29 |
09:48 ET | 1576 | 16.24 |
09:50 ET | 2261 | 16.2 |
09:52 ET | 755 | 16.18 |
09:54 ET | 4212 | 16.2473 |
09:56 ET | 3614 | 16.22 |
09:57 ET | 300 | 16.225 |
09:59 ET | 1500 | 16.215 |
10:01 ET | 600 | 16.22 |
10:03 ET | 900 | 16.215 |
10:06 ET | 1300 | 16.21 |
10:08 ET | 4050 | 16.17 |
10:10 ET | 200 | 16.16 |
10:12 ET | 1748 | 16.17 |
10:14 ET | 846 | 16.18 |
10:15 ET | 600 | 16.2 |
10:17 ET | 6000 | 16.24 |
10:19 ET | 2563 | 16.23 |
10:21 ET | 1353 | 16.21 |
10:24 ET | 2188 | 16.19 |
10:26 ET | 2507 | 16.18 |
10:28 ET | 2243 | 16.14 |
10:30 ET | 4370 | 16.15 |
10:32 ET | 3445 | 16.18 |
10:33 ET | 1833 | 16.155 |
10:35 ET | 1900 | 16.17 |
10:37 ET | 1590 | 16.18 |
10:39 ET | 2000 | 16.15 |
10:42 ET | 500 | 16.185 |
10:44 ET | 222 | 16.18 |
10:46 ET | 200 | 16.19 |
10:48 ET | 10390 | 16.21 |
10:50 ET | 759 | 16.23 |
10:51 ET | 1460 | 16.235 |
10:53 ET | 1004 | 16.21 |
10:55 ET | 1086 | 16.16 |
10:57 ET | 1728 | 16.15 |
11:00 ET | 1713 | 16.1599 |
11:02 ET | 803 | 16.16 |
11:04 ET | 3268 | 16.13 |
11:06 ET | 8020 | 16.11 |
11:08 ET | 1355 | 16.12 |
11:11 ET | 12907 | 16.08 |
11:13 ET | 18330 | 16.05 |
11:15 ET | 1608 | 16.055 |
11:18 ET | 1150 | 16.03 |
11:20 ET | 100 | 16.05 |
11:22 ET | 1200 | 16.04 |
11:24 ET | 1250 | 16.045 |
11:26 ET | 954 | 16.04 |
11:27 ET | 900 | 16.0677 |
11:29 ET | 1500 | 16.06 |
11:31 ET | 1400 | 16.07 |
11:33 ET | 1000 | 16.07 |
11:36 ET | 1788 | 16.06 |
11:38 ET | 1262 | 16.06 |
11:40 ET | 3002 | 16.05 |
11:42 ET | 3250 | 16.0796 |
11:44 ET | 700 | 16.06 |
11:45 ET | 1945 | 16.07 |
11:47 ET | 1200 | 16.0873 |
11:49 ET | 3199 | 16.07 |
11:51 ET | 2449 | 16.1 |
11:54 ET | 450 | 16.125 |
11:56 ET | 715 | 16.13 |
11:58 ET | 200 | 16.14 |
12:02 ET | 900 | 16.15 |
12:03 ET | 1591 | 16.15 |
12:05 ET | 300 | 16.15 |
12:09 ET | 1844 | 16.14 |
12:12 ET | 750 | 16.14 |
12:14 ET | 1907 | 16.13 |
12:16 ET | 921 | 16.13 |
12:18 ET | 4221 | 16.14 |
12:20 ET | 538 | 16.16 |
12:21 ET | 1364 | 16.175 |
12:23 ET | 817 | 16.21 |
12:25 ET | 1291 | 16.24 |
12:27 ET | 794 | 16.25 |
12:30 ET | 600 | 16.25 |
12:32 ET | 300 | 16.23 |
12:34 ET | 1537 | 16.2599 |
12:36 ET | 2227 | 16.24 |
12:38 ET | 1084 | 16.24 |
12:39 ET | 1776 | 16.22 |
12:41 ET | 805 | 16.23 |
12:43 ET | 400 | 16.24 |
12:45 ET | 300 | 16.22 |
12:48 ET | 824 | 16.23 |
12:50 ET | 1201 | 16.23 |
12:52 ET | 500 | 16.23 |
12:54 ET | 100 | 16.23 |
12:56 ET | 200 | 16.23 |
12:57 ET | 980 | 16.23 |
12:59 ET | 800 | 16.24 |
01:01 ET | 1099 | 16.24 |
01:03 ET | 200 | 16.23 |
01:06 ET | 1383 | 16.25 |
01:08 ET | 1915 | 16.24 |
01:10 ET | 300 | 16.245 |
01:12 ET | 921 | 16.23 |
01:14 ET | 500 | 16.23 |
01:15 ET | 2956 | 16.25 |
01:17 ET | 5562 | 16.27 |
01:19 ET | 7236 | 16.29 |
01:21 ET | 1339 | 16.29 |
01:24 ET | 4801 | 16.3 |
01:26 ET | 2553 | 16.31 |
01:28 ET | 3300 | 16.3045 |
01:30 ET | 1750 | 16.28 |
01:32 ET | 2064 | 16.27 |
01:33 ET | 1600 | 16.26 |
01:35 ET | 1200 | 16.22 |
01:37 ET | 1391 | 16.24 |
01:39 ET | 2715 | 16.26 |
01:42 ET | 716 | 16.25 |
01:44 ET | 900 | 16.27 |
01:46 ET | 200 | 16.28 |
01:48 ET | 1513 | 16.29 |
01:50 ET | 1000 | 16.26 |
01:51 ET | 3870 | 16.25 |
01:53 ET | 4281 | 16.25 |
01:55 ET | 6764 | 16.27 |
01:57 ET | 10300 | 16.25 |
02:00 ET | 2434 | 16.265 |
02:02 ET | 2250 | 16.25 |
02:04 ET | 376 | 16.25 |
02:06 ET | 200 | 16.25 |
02:08 ET | 700 | 16.26 |
02:09 ET | 1925 | 16.265 |
02:11 ET | 500 | 16.26 |
02:13 ET | 1719 | 16.29 |
02:15 ET | 1837 | 16.31 |
02:18 ET | 7375 | 16.29 |
02:22 ET | 16704 | 16.32 |
02:24 ET | 1500 | 16.3 |
02:26 ET | 3534 | 16.3 |
02:27 ET | 1449 | 16.304 |
02:29 ET | 2100 | 16.34 |
02:31 ET | 1900 | 16.315 |
02:33 ET | 1100 | 16.32 |
02:36 ET | 3852 | 16.32 |
02:38 ET | 2085 | 16.31 |
02:40 ET | 2041 | 16.3 |
02:42 ET | 1176 | 16.3156 |
02:44 ET | 1983 | 16.29 |
02:45 ET | 600 | 16.3 |
02:47 ET | 3274 | 16.295 |
02:49 ET | 1300 | 16.3 |
02:51 ET | 4192 | 16.28 |
02:54 ET | 1349 | 16.3 |
02:56 ET | 10940 | 16.3 |
02:58 ET | 12871 | 16.31 |
03:00 ET | 6505 | 16.31 |
03:02 ET | 5475 | 16.3 |
03:03 ET | 1297 | 16.3 |
03:05 ET | 1600 | 16.305 |
03:07 ET | 1606 | 16.3022 |
03:09 ET | 8100 | 16.3 |
03:12 ET | 2317 | 16.3 |
03:14 ET | 600 | 16.3 |
03:16 ET | 2100 | 16.28 |
03:18 ET | 5309 | 16.26 |
03:20 ET | 2519 | 16.24 |
03:21 ET | 27835 | 16.24 |
03:23 ET | 607 | 16.24 |
03:25 ET | 2628 | 16.23 |
03:27 ET | 6976 | 16.2 |
03:30 ET | 4035 | 16.23 |
03:32 ET | 4215 | 16.2 |
03:34 ET | 3146 | 16.15 |
03:36 ET | 9426 | 16.16 |
03:38 ET | 2012 | 16.145 |
03:39 ET | 4474 | 16.1377 |
03:41 ET | 3205 | 16.14 |
03:43 ET | 5253 | 16.165 |
03:45 ET | 5514 | 16.16 |
03:48 ET | 3738 | 16.17 |
03:50 ET | 8341 | 16.16 |
03:52 ET | 16501 | 16.25 |
03:54 ET | 24950 | 16.25 |
03:56 ET | 12668 | 16.235 |
03:57 ET | 14550 | 16.255 |
03:59 ET | 17950 | 16.25 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.7B | -1,262.6x | --- |
Azenta Inc | 2.8B | -19.2x | --- |
PTC Therapeutics Inc | 2.3B | -4.0x | --- |
Guardant Health Inc | 3.5B | -7.4x | --- |
Amicus Therapeutics Inc | 2.9B | -20.1x | --- |
Novavax Inc | 1.8B | -4.0x | --- |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $813.8M |
Shares Outstanding | 165.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $-0.01 |
Book Value | $2.62 |
P/E Ratio | -1,262.6x |
Price/Sales (TTM) | 3.3 |
Price/Cash Flow (TTM) | 300.2x |
Operating Margin | -0.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.